{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:38:55Z","timestamp":1794559135059,"version":"4.9.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18ck0106420h0001"],"award-info":[{"award-number":["18ck0106420h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"F. Hoffmann-La Roche Ltd | Chugai Pharmaceutical","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-00918-1","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:03:10Z","timestamp":1739941390000},"page":"445-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma \u2013 a multicenter phase 2 trial (EPOC1802)"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-2765","authenticated-orcid":false,"given":"Hideaki","family":"Bando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4196-555X","authenticated-orcid":false,"given":"Daisuke","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Irie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Itahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3764-0517","authenticated-orcid":false,"given":"Yosuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Habu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Fukaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-5309","authenticated-orcid":false,"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-5072","authenticated-orcid":false,"given":"Ken","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisho","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6072-0144","authenticated-orcid":false,"given":"Shun-ichiro","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4431-8892","authenticated-orcid":false,"given":"Masaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenobu","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Fuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6897-9417","authenticated-orcid":false,"given":"Shohei","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4645-0181","authenticated-orcid":false,"given":"Hiroyuki","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6563-9807","authenticated-orcid":false,"given":"Hiroyoshi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-4756","authenticated-orcid":false,"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2554-8334","authenticated-orcid":false,"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"918_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"918_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10388-019-00674-z","volume":"16","author":"Y Tachimori","year":"2019","unstructured":"Tachimori, Y. et al. Comprehensive registry of esophageal cancer in Japan, 2012. Esophagus 16, 221\u2013245 (2019).","journal-title":"Esophagus"},{"key":"918_CR3","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannova","year":"2022","unstructured":"Obermannova, R. et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 992\u20131004 (2022).","journal-title":"Ann. Oncol."},{"key":"918_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-018-0641-9","volume":"16","author":"Y Kitagawa","year":"2019","unstructured":"Kitagawa, Y. et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus 16, 1\u201324 (2019).","journal-title":"Esophagus"},{"key":"918_CR5","doi-asserted-by":"publisher","unstructured":"Ajani, J. A. et al. Esophageal and esophagogastric junction cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. https:\/\/doi.org\/10.6004\/jnccn.2023.0019 (2023).","DOI":"10.6004\/jnccn.2023.0019"},{"key":"918_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/jjco\/hyh107","volume":"34","author":"K Ishida","year":"2004","unstructured":"Ishida, K., Ando, N., Yamamoto, S., Ide, H. & Shinoda, M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)\/Japan Clinical Oncology Group trial (JCOG9516). Jpn J. Clin. Oncol. 34, 615\u2013619 (2004).","journal-title":"Jpn J. Clin. Oncol."},{"key":"918_CR7","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1200\/JCO.1999.17.9.2915","volume":"17","author":"A Ohtsu","year":"1999","unstructured":"Ohtsu, A. et al. Definitive chemoradiotherapy for T4 and\/or M1 lymph node squamous cell carcinoma of the esophagus. J. Clin. Oncol. 17, 2915\u20132921 (1999).","journal-title":"J. Clin. Oncol."},{"key":"918_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/cas.12622","volume":"106","author":"M Shinoda","year":"2015","unstructured":"Shinoda, M. et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 106, 407\u2013412 (2015).","journal-title":"Cancer Sci."},{"key":"918_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10388-023-00987-0","volume":"20","author":"T Habu","year":"2023","unstructured":"Habu, T. et al. Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma. Esophagus 20, 533\u2013540 (2023).","journal-title":"Esophagus"},{"key":"918_CR10","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","volume":"326","author":"A Herskovic","year":"1992","unstructured":"Herskovic, A. et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 326, 1593\u20131598 (1992).","journal-title":"N. Engl. J. Med."},{"key":"918_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki, Y. et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386, 449\u2013462 (2022).","journal-title":"N. Engl. J. Med."},{"key":"918_CR12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun, J. M. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759\u2013771 (2021).","journal-title":"Lancet"},{"key":"918_CR13","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly, R. J. et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 384, 1191\u20131203 (2021).","journal-title":"N. Engl. J. Med."},{"key":"918_CR14","doi-asserted-by":"publisher","unstructured":"Shah, M. A., Hofstetter, W. L. & Kennedy, E. B. Immunotherapy in patients with locally advanced esophageal carcinoma: ASCO treatment of locally advanced esophageal carcinoma guideline rapid recommendation update. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/jco.21.01831 (2021).","DOI":"10.1200\/jco.21.01831"},{"key":"918_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687\u2013695 (2014).","journal-title":"J. Clin. Invest."},{"key":"918_CR16","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458\u20135468 (2014).","journal-title":"Cancer Res."},{"key":"918_CR17","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.molimm.2007.08.013","volume":"45","author":"P Zhang","year":"2008","unstructured":"Zhang, P., Su, D. M., Liang, M. & Fu, J. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol. Immunol. 45, 1470\u20131476 (2008).","journal-title":"Mol. Immunol."},{"key":"918_CR18","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919\u20131929 (2017).","journal-title":"N. Engl. J. Med."},{"key":"918_CR19","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379, 2342\u20132350 (2018).","journal-title":"N. Engl. J. Med."},{"key":"918_CR20","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843\u2013852 (2014).","journal-title":"Immunity"},{"key":"918_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie, K. J. et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 548, 461\u2013465 (2017).","journal-title":"Nature"},{"key":"918_CR22","doi-asserted-by":"publisher","first-page":"26496","DOI":"10.18632\/oncotarget.8420","volume":"7","author":"DR Ranoa","year":"2016","unstructured":"Ranoa, D. R. et al. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget 7, 26496\u201326515 (2016).","journal-title":"Oncotarget"},{"key":"918_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-021-03269-w","volume":"591","author":"M Tigano","year":"2021","unstructured":"Tigano, M., Vargas, D. C., Tremblay-Belzile, S., Fu, Y. & Sfeir, A. Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance. Nature 591, 477\u2013481 (2021).","journal-title":"Nature"},{"key":"918_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi, A. B. et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol. Res. 3, 345\u2013355 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"918_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"918_CR26","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","volume":"30","author":"M Miyara","year":"2009","unstructured":"Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899\u2013911 (2009).","journal-title":"Immunity"},{"key":"918_CR27","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41590-022-01219-w","volume":"23","author":"D Zehn","year":"2022","unstructured":"Zehn, D., Thimme, R., Lugli, E., de Almeida, G. P. & Oxenius, A. \u2018Stem-like\u2019 precursors are the fount to sustain persistent CD8(+) T cell responses. Nat. Immunol. 23, 836\u2013847 (2022).","journal-title":"Nat. Immunol."},{"key":"918_CR28","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","volume":"171","author":"MJ Topper","year":"2017","unstructured":"Topper, M. J. et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell 171, 1284\u20131300.e1221 (2017).","journal-title":"Cell"},{"key":"918_CR29","doi-asserted-by":"publisher","unstructured":"Kumagai, S. et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2022.01.001 (2022).","DOI":"10.1016\/j.ccell.2022.01.001"},{"key":"918_CR30","doi-asserted-by":"publisher","unstructured":"Sugiyama, E. et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aav3937 (2020).","DOI":"10.1126\/sciimmunol.aav3937"},{"key":"918_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202\u2013216 (2016).","journal-title":"Cancer Discov."},{"key":"918_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2021.12.005","volume":"185","author":"A Marzio","year":"2022","unstructured":"Marzio, A. et al. EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion. Cell 185, 169\u2013183.e119 (2022).","journal-title":"Cell"},{"key":"918_CR33","doi-asserted-by":"publisher","unstructured":"Collins, N. B. et al. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-003402 (2022).","DOI":"10.1136\/jitc-2021-003402"},{"key":"918_CR34","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"918_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ccr.2009.01.023","volume":"15","author":"C Kudo-Saito","year":"2009","unstructured":"Kudo-Saito, C., Shirako, H., Takeuchi, T. & Kawakami, Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15, 195\u2013206 (2009).","journal-title":"Cancer Cell"},{"key":"918_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2353\/ajpath.2010.090952","volume":"177","author":"SS Sume","year":"2010","unstructured":"Sume, S. S., Kantarci, A., Lee, A., Hasturk, H. & Trackman, P. C. Epithelial to mesenchymal transition in gingival overgrowth. Am. J. Pathol. 177, 208\u2013218 (2010).","journal-title":"Am. J. Pathol."},{"key":"918_CR37","first-page":"1103","volume":"43","author":"K Wang","year":"2020","unstructured":"Wang, K. et al. Knockdown of MMP\u20111 inhibits the progression of colorectal cancer by suppressing the PI3K\/Akt\/c\u2011myc signaling pathway and EMT. Oncol. Rep. 43, 1103\u20131112 (2020).","journal-title":"Oncol. Rep."},{"key":"918_CR38","doi-asserted-by":"publisher","first-page":"23519","DOI":"10.18632\/oncotarget.25240","volume":"9","author":"J Konge","year":"2018","unstructured":"Konge, J. et al. Breast cancer stem cell-like cells generated during TGF\u03b2-induced EMT are radioresistant. Oncotarget 9, 23519\u201323531 (2018).","journal-title":"Oncotarget"},{"key":"918_CR39","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai, S. et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 21, 1346\u20131358 (2020).","journal-title":"Nat. Immunol."},{"key":"918_CR40","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ccr.2008.10.011","volume":"14","author":"S Tu","year":"2008","unstructured":"Tu, S. et al. Overexpression of interleukin-1\u03b2 induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14, 408\u2013419 (2008).","journal-title":"Cancer Cell"},{"key":"918_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2022.01.004","volume":"40","author":"AM Nicolas","year":"2022","unstructured":"Nicolas, A. M. et al. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell 40, 168\u2013184.e113 (2022).","journal-title":"Cancer Cell"},{"key":"918_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu, X. et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10, 48\u201357 (2009).","journal-title":"Nat. Immunol."},{"key":"918_CR43","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-022-04718-w","volume":"605","author":"F Mair","year":"2022","unstructured":"Mair, F. et al. Extricating human tumour immune alterations from tissue inflammation. Nature 605, 728\u2013735 (2022).","journal-title":"Nature"},{"key":"918_CR44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","volume":"24","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y. et al. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. Lancet Oncol. 24, 371\u2013382 (2023).","journal-title":"Lancet Oncol."},{"key":"918_CR45","doi-asserted-by":"publisher","first-page":"e1356153","DOI":"10.1080\/2162402X.2017.1356153","volume":"6","author":"A Oweida","year":"2017","unstructured":"Oweida, A. et al. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology 6, e1356153 (2017).","journal-title":"Oncoimmunology"},{"key":"918_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/ajco.13688","volume":"19","author":"H Guan","year":"2023","unstructured":"Guan, H. et al. Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy. Asia Pac. J. Clin. Oncol. 19, 35\u201350 (2023).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"918_CR47","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4049\/jimmunol.1200563","volume":"189","author":"A Gupta","year":"2012","unstructured":"Gupta, A. et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J. Immunol. 189, 558\u2013566 (2012).","journal-title":"J. Immunol."},{"key":"918_CR48","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada, T. et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc. Natl Acad. Sci. USA 116, 9999\u201310008 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"918_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abk0957","volume":"7","author":"K Itahashi","year":"2022","unstructured":"Itahashi, K. et al. BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci. Immunol. 7, eabk0957 (2022).","journal-title":"Sci. Immunol."},{"key":"918_CR50","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","volume":"1","author":"I Solomon","year":"2020","unstructured":"Solomon, I. et al. CD25-T(reg)-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat. Cancer 1, 1153\u20131166 (2020).","journal-title":"Nat. Cancer"},{"key":"918_CR51","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1073\/pnas.1812266115","volume":"116","author":"I Kaplanov","year":"2019","unstructured":"Kaplanov, I. et al. Blocking IL-1\u03b2 reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc. Natl Acad. Sci. USA 116, 1361\u20131369 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"918_CR52","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332, 600\u2013603 (2011).","journal-title":"Science"},{"key":"918_CR53","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373\u2013377 (2015).","journal-title":"Nature"},{"key":"918_CR54","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti, S. C. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 24, 1845\u20131851 (2018).","journal-title":"Nat. Med."},{"key":"918_CR55","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","volume":"7","author":"M Grapin","year":"2019","unstructured":"Grapin, M. et al. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J Immunother. Cancer 7, 160 (2019).","journal-title":"J Immunother. Cancer"},{"key":"918_CR56","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ncponc0252","volume":"2","author":"LM McShane","year":"2005","unstructured":"McShane, L. M. et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Oncol. 2, 416\u2013422 (2005).","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"918_CR57","doi-asserted-by":"publisher","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","volume":"7","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F., Altman, D. G., Moher, D. & CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 7, e1000251 (2010).","journal-title":"PLoS Med."},{"key":"918_CR58","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1245\/s10434-020-09181-3","volume":"28","author":"N Sudo","year":"2021","unstructured":"Sudo, N. et al. Clinical utility of ypTNM stage grouping in the 8th Edition of the American Joint Committee on Cancer TNM staging system for esophageal squamous cell carcinoma. Ann. Surg. Oncol. 28, 650\u2013660 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"918_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06716-5","volume":"20","author":"H Bando","year":"2020","unstructured":"Bando, H. et al. TENERGY: multicenter phase II study of atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma. BMC Cancer 20, 336 (2020).","journal-title":"BMC Cancer"},{"key":"918_CR60","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"918_CR61","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"918_CR62","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/ng.3224","volume":"47","author":"C Isella","year":"2015","unstructured":"Isella, C. et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 47, 312\u2013319 (2015).","journal-title":"Nat. Genet."},{"key":"918_CR63","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."},{"key":"918_CR64","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","volume":"26","author":"R Dummer","year":"2020","unstructured":"Dummer, R. et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat. Med. 26, 1557\u20131563 (2020).","journal-title":"Nat. Med."},{"key":"918_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101557","volume":"3","author":"T Kobayashi","year":"2022","unstructured":"Kobayashi, T. et al. Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization. STAR Protoc. 3, 101557 (2022).","journal-title":"STAR Protoc"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00918-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00918-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00918-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T12:26:24Z","timestamp":1743337584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00918-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":65,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-00918-1","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.B. reports research funding from Ono Pharmaceutical and honoraria from Ono Pharmaceutical, Eli Lilly Japan and Taiho Pharmaceutical. S. Kumagai received honoraria from MSD and Chugai Pharmaceutical. S.M. received honoraria from Eli Lilly, Merck Biopharma and Chugai Pharmaceutical. K.I. received honoraria from MSD and Chugai Pharmaceutical. T.T. received honoraria from Ono Pharmaceutical, Bristol Myers Squibb, MSD and Taiho Pharmaceuticals. H. Hara reported honoraria from Asahi-Kasei, Bayer, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Lilly, Merck Biopharma, MSD, Ono, Taiho, Takeda and Yakult; consulting or advisory roles from Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo and Ono; and research grants from ALX Oncology, Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Janssen, MSD, Ono and Taiho. S. Kadowaki reports grants from Ono Pharmaceutical, Taiho Pharmaceutical, MSD, Nobel Pharmaceutical, Janssen Pharmaceutical, Bayer, Eli Lilly, Chugai Pharmaceutical and Daiichi Sankyo, and honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, MSD, Daiichi Sankyo, Merck KgaA, Bristol Myers Squibb, Eli Lilly, Chugai Pharmaceutical, Bayer and Esai. K.K. reports consulting fees from Ono Pharmaceutical, Bristol Myers Squibb, Beigene\/Novartis, AstraZeneca, Roche, BAYER, Merck & Co., Merck Biopharma and Janssen; and honoraria from Ono Pharmaceutical and Bristol Myers Squibb. K.C. received grants from Bristol Myers Squibb and Ono for this study and honoraria from Bristol Myers Squibb, Chugai, Ono and Taiho outside of the submitted work. M.N. received personal fees from AstraZeneca, MSD, Varian Medical Systems and Illumina outside the submitted work. M.W. reports honoraria from Nihon Media Physics. S. Koyama reports receiving research funding from Otsuka Pharmaceutical and Chugai Pharmaceutical. H.M. received research funding from Ono Pharmaceutical, PFDeNA, Konica-Minolta, Ambry Genetics, Chugai, Guardant Health and Riken Genesis outside this study; and also serves as a board member of CureGene outside this study. H.N. received research funding and honoraria (lecture fees) from Ono Pharmaceutical, Bristol Myers Squibb, Chugai Pharmaceutical and MSD; honoraria (lecture fees) from Amgen; and research funding from Taiho Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, Zenyaku Kogyo, Oncolys BioPharma, Debiopharma, Asahi-Kasei, Sysmex, Fujifilm, SRL, Astellas Pharmaceutical, Sumitomo Dainippon Pharma and BD Japan outside this study. He also serves as a board member and founder of Sustainable Cell Therapeutics and Cellian-Biclo outside this study. K.S. reports receiving personal fees for advisory roles from Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, Merck Pharmaceutical, Taiho Pharmaceutical, Astellas, Novartis, AbbVie, GSK, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan and Janssen; receiving honoraria (lecture fees) from Takeda, Bristol Myers Squibb and Janssen; and receiving research funding from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Medi Science, Eisai and Amgen, outside the submitted work. T.Y. reports research funding from Taiho, Ono, Chugai, Amgen, MSD, Daiichi Sankyo, Eisai, FALCO Biosystems, Genomedia, Molecular Health, Nippon Boehringer Ingelheim, Pfizer, Roche Diagnostics, Sysmex and Sanofi and honoraria from Bayer, Chugai, Merck Biopharma, MSD, Ono and Takeda. T.K. reports honoraria from Ono Pharmaceutical, Covidien Japan, MSD, Boehringer Ingelheim, Kyowa Kirin, EA Pharma, Bristol Myers Squibb, 3H Clinical Trial, AstraZeneca, Taiho Pharmaceutical, LiangYiHui Healthcare, Oncology News China, Japanese Society of Pharmaceutical Health Care and Sciences, Oncolys BioPharma and BMS; and research grants from Beigene Ltd., AstraZeneca, Chugai Pharmaceutical, Parexel International, Shionogi, Taiho Pharmaceutical, Astellas Amgen BioPharma, MSD and Ono Pharmaceutical. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}